Faron Pharmaceuticals Oy Equity Research & Stock Reports

Equity Research, Broker Reports, and media content on Faron Pharmaceuticals Oy

Access the latest forecasts, broker valuations, multiples, and video content from the city about Faron Pharmaceuticals Oy
See live updates from analysts, company announcements, and other news in a personalised/single dashboard

11 Jul 24

Faron Pharmaceuticals CEO shares positive feedback from US FDA for Phase III BEXMAB trial

24 Jun 24

Faron Pharmaceuticals CEO says €30.7 million fundraise was an 'amazing achievement'

02 May 24

Faron Pharmaceuticals' new CEO Dr Juho Jalkanen sets bold vision for 2024

22 Apr 24

PANMURE: Healthcare: Prescribed Reading : Mixed messages

Companies: KOO 13 FDBK AMS EKF ANCR AGY CVSG SCLP COG OXB DXRX AREC FARON BVX 8091

Panmure Liberum

18 Mar 24

Faron Pharmaceuticals reports promising phase 1 results from BEXMAB study

14 Mar 24

PANMURE: Faron Pharmaceuticals : Next BEXMAB data 19th March

Companies: Faron Pharmaceuticals Oy

Panmure Liberum

04 Mar 24

Hybridan Small Cap Feast - 04 Mar 24

4th March 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objecti

Companies: FARN BEM BRH HUW AUTG TGP QTX CMCL

Hybridan

23 Feb 24

PANMURE: Healthcare: Prescribed Reading : The results preview edition

Companies: KOO 13 FDBK AMS EKF ANCR AGY CVSG SCLP COG OXB DXRX AREC FARON BVX 8091

Panmure Liberum

20 Feb 24

PANMURE: Faron Pharmaceuticals : Moving to Under Review

Companies: Faron Pharmaceuticals Oy

Panmure Liberum

01 Feb 24

Faron Pharmaceuticals presents at the Proactive One2One Investor Conference - January 25th

01 Feb 24

Faron Pharmaceuticals outlines groundbreaking work in cancer treatment - presentation

29 Jan 24

Faron Pharmaceuticals reports promising outcomes in cancer treatment trials; aiming for FDA approval

09 Jan 24

PANMURE: Healthcare: Prescribed Reading : 2024 - a year of delivery

Companies: KOO 13 FDBK AMS EKF ANCR AGY CVSG SCLP COG OXB DXRX AREC FARON BVX 8091

Panmure Liberum

11 Dec 23

Faron Pharmaceuticals presents "very positive" Phase 1 data at ASH Conference

06 Nov 23

Hybridan Small Cap Feast - 06 Nov 23

6th November 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje

Companies: ROQ FARN POS SDI PHE TENG SPR CELH

Hybridan